Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis (Q30300234)

15 June 2017

1 reference

1 reference

1 reference

title

Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis (English)

1 reference

15 June 2017

1 reference

1 reference

1 reference

Mahmoud H Mosli

1

0 references

Brian G. Feagan

8

object named as

Brian G Feagan

1 reference

15 June 2017

John K MacDonald

2

1 reference

15 June 2017

Stephen J Bickston

3

1 reference

15 June 2017

Brian W Behm

4

1 reference

15 June 2017

David J Tsoulis

5

1 reference

15 June 2017

Jianfeng Cheng

6

1 reference

15 June 2017

Reena Khanna

7

1 reference

15 June 2017

publication date

1 May 2015

1 reference

Inflammatory Bowel Diseases

15 June 2017

published in

1 reference

15 June 2017

volume

21

1 reference

15 June 2017

issue

5

1 reference

15 June 2017

page(s)

1151-1159

1 reference

T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects

15 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Its binding motif for alpha 4 beta 7 and role in experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1097/MIB.0000000000000396

10.1097/MIB.0000000000000396

21 January 2018

Identifiers

DOI

1 reference

15 June 2017

1 reference